413 related articles for article (PubMed ID: 31992691)
21. [Venetoclax combined with hypomethylating agents induced tumor lysis syndrome in patients with acute leukemia: 7 cases report and literature review].
Guo YS; Zhao CH; Hu DY; Shen K; Chen SN
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):508-511. PubMed ID: 37550210
[No Abstract] [Full Text] [Related]
22. A Real-life Turkish Experience of Venetoclax Treatment in High-risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Gemici A; Ozkalemkas F; Dogu MH; Tekinalp A; Alacacioglu I; Guney T; Ince I; Geduk A; Cagliyan GA; Maral S; Serin I; Gunduz E; Karakus V; Bekoz HS; Eren R; Pinar IE; Gunes AK; Sargın FD; Sevindik OG
Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):e686-e692. PubMed ID: 34059487
[TBL] [Abstract][Full Text] [Related]
23. BCL-2 inhibition in AML: an unexpected bonus?
Konopleva M; Letai A
Blood; 2018 Sep; 132(10):1007-1012. PubMed ID: 30037885
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of venetoclax combined with hypomethylating agents in young, and unfit patients with newly diagnosed core binding factor acute myeloid leukemia.
Zhang K; Zhang X; Xu Y; Xue S; Qiu H; Tang X; Han Y; Chen S; Sun A; Zhang Y; Wu D; Wang Y
Blood Cancer J; 2023 Oct; 13(1):155. PubMed ID: 37821435
[No Abstract] [Full Text] [Related]
25. Is the overall survival for older adults with AML finally improving?
Lancet JE
Best Pract Res Clin Haematol; 2018 Dec; 31(4):387-390. PubMed ID: 30466753
[TBL] [Abstract][Full Text] [Related]
26. Double remission of chronic lymphocytic leukemia and secondary acute myeloid leukemia after venetoclax monotherapy: A case report.
Wang L; Lin N
Medicine (Baltimore); 2021 Feb; 100(6):e24703. PubMed ID: 33578607
[TBL] [Abstract][Full Text] [Related]
27. Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia.
Cathelin S; Sharon D; Subedi A; Cojocari D; Phillips DC; Leverson JD; MacBeth KJ; Nicolay B; Narayanaswamy R; Ronseaux S; Liu G; Chan SM
Leukemia; 2022 Mar; 36(3):869-872. PubMed ID: 34743189
[No Abstract] [Full Text] [Related]
28. Apoptosis targeted therapies in acute myeloid leukemia: an update.
Ball S; Borthakur G
Expert Rev Hematol; 2020 Dec; 13(12):1373-1386. PubMed ID: 33205684
[No Abstract] [Full Text] [Related]
29. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
30.
Corradi G; Forte D; Cristiano G; Polimeno A; Ciciarello M; Salvestrini V; Bandini L; Robustelli V; Ottaviani E; Cavo M; Ocadlikova D; Curti A
Front Immunol; 2024; 15():1386517. PubMed ID: 38812504
[TBL] [Abstract][Full Text] [Related]
31. Venetoclax-based combinations for acute myeloid leukemia: optimizing their use in Latin-America.
Gómez-De León A; Demichelis-Gómez R; Pinedo-Rodríguez A; Enriquez-Vera D; Flores-Jiménez JA; Ceballos-López AA; Rodríguez-Mejorada M; Herrera Riojas MA; Ovilla-Martínez R; Báez-Islas P; Cota-Rangel X; Neme-Yunes Y; Inclán-Alarcón S; López-Flores NJ; Colunga-Pedraza PR; Rodríguez-Zúñiga AC; Gómez-Almaguer D
Hematology; 2022 Dec; 27(1):249-257. PubMed ID: 35192778
[No Abstract] [Full Text] [Related]
32. Molecular predictors of response to venetoclax plus hypomethylating agent in treatment-naïve acute myeloid leukemia.
Gangat N; Johnson I; McCullough K; Farrukh F; Al-Kali A; Alkhateeb H; Begna K; Mangaonkar A; Litzow M; Hogan W; Shah M; Patnaik M; Pardanani A; Tefferi A
Haematologica; 2022 Oct; 107(10):2501-2505. PubMed ID: 35770533
[No Abstract] [Full Text] [Related]
33. Venetoclax and hypomethylating agents yield high response rates and favourable transplant outcomes in patients with newly diagnosed acute myeloid leukaemia.
Salhotra A; Tsai NC; Zhang J; Ngo D; Aribi A; Sandhu K; Ball B; Al-Malki M; Ali H; Koller P; Artz A; Forman S; Nakamura R; Stein A; Marcucci G; Aldoss I; Pullarkat V
Br J Haematol; 2022 Mar; 196(6):e71-e74. PubMed ID: 34931310
[No Abstract] [Full Text] [Related]
34. Acute myeloid leukemia drug development in the post-venetoclax era.
Pollyea DA
Am J Hematol; 2019 Sep; 94(9):959-962. PubMed ID: 31179583
[No Abstract] [Full Text] [Related]
35. Venetoclax-based combinations for the treatment of newly diagnosed acute myeloid leukemia.
Othman TA; Azenkot T; Moskoff BN; Tenold ME; Jonas BA
Future Oncol; 2021 Aug; 17(23):2989-3005. PubMed ID: 34024158
[TBL] [Abstract][Full Text] [Related]
36. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
[No Abstract] [Full Text] [Related]
37. Hypomethylating agents and venetoclax in acute myeloid leukemia.
DiNardo CD
Clin Adv Hematol Oncol; 2021 Feb; 19(2):82-83. PubMed ID: 33596188
[No Abstract] [Full Text] [Related]
38. How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia.
Jonas BA; Pollyea DA
Leukemia; 2019 Dec; 33(12):2795-2804. PubMed ID: 31628431
[TBL] [Abstract][Full Text] [Related]
39. New Treatment Options for Older Patients with Acute Myeloid Leukemia.
Saxena K; Konopleva M
Curr Treat Options Oncol; 2021 Mar; 22(5):39. PubMed ID: 33743079
[TBL] [Abstract][Full Text] [Related]
40. Smart and Generalizable Cytarabine Derivative-Triggered Nanoparticles for Synergistic Therapy of Relapsed/Refractory Acute Myeloid Leukemia.
Jia L; Yang H; Zheng D; Ye J; Zhou Q; Li G; Zhou Y; Yang X; Liu J; Ye F; Song Y; Ma D; Ji C
ACS Appl Mater Interfaces; 2023 Jun; 15(23):27624-27637. PubMed ID: 37249260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
